The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study.
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Giovanni Marconi
Employment - University of Bologna, Bologna, Italy
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; ImmunoGen; Janssen; Menarini Group; Pfizer; Ryvu Therapeutics; SERVIER; Syros Pharmaceuticals; Takeda
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; ImmunoGen; Janssen; Menarini Group; Pfizer; Ryvu Therapeutics; SERVIER; Syros Pharmaceuticals; Takeda
Speakers' Bureau - Abbvie; Astellas Pharma; AstraZeneca; ImmunoGen; Janssen; Menarini Group; Pfizer; Ryvu Therapeutics; Syros Pharmaceuticals; Takeda
Research Funding - Abbvie; AstraZeneca; Daiichi Sankyo; Jazz Pharmaceuticals; MEI Pharma; Pfizer
Travel, Accommodations, Expenses - Jazz Pharmaceuticals; Kura Oncology
 
Pau Montesinos
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Jazz Pharmaceuticals; Otsuka; Pfizer; SERVIER
Speakers' Bureau - Celgene; Daiichi Sankyo; Otsuka
Research Funding - Abbvie (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen
 
Andrew Lane
Stock and Other Ownership Interests - Stelexis BioSciences, Inc.
Consulting or Advisory Role - Cimeio Therapeutics; IDRx; Jnana Therapeutics; ProteinQure; Qiagen
Research Funding - Abbvie; Stemline Therapeutics
 
Luca Mazzarella
No Relationships to Disclose
 
David Sallman
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; AvenCell; Bluebird Bio; Bristol-Myers Squibb; Dark Blue Therapeutics; Debiopharm Group; Geron; Johnson & Johnson/Janssen; Molecular Partners; Novartis; Servier; Shattuck Labs; Syndax; Syros Pharmaceuticals; Taiho Oncology
Speakers' Bureau - Incyte
Research Funding - Aprea Therapeutics (Inst); Jazz Pharmaceuticals
 
Matthew Ulrickson
Consulting or Advisory Role - ADC Therapeutics; Autolus; Bristol-Myers Squibb/Celgene/Juno; Genentech; Kura Oncology; Stemline Therapeutics
Research Funding - Immunogen; Kite, a Gilead company
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Gary Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Autolus Therapeutics; Bristol-Myers Squibb/Celgene; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical; Rigel
Speakers' Bureau - Abbvie; Agios; Amgen; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Rigel; Sanofi; Seattle Genetics/Astellas; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Aptevo Therapeutics; Arog; Astellas Pharma; AVM Biotechnology; Bio-Path Holdings; Biomea Fusion; Biosight; Bristol-Myers Squibb/Celgene; Celator; Cellectis; Celularity; Cogent Biosciences; Constellation Pharmaceuticals; Cullinan Oncology; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; Fate therapuetics; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; glycomimetics; Immune-Onc Therapeutics; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Kronos Bio; Kura Oncology; Loxo; Marker Therapeutics; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Harry Erba
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb/Celgene; Celgene; Daiichi Sankyo; Glycomimetics; Immunogen; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Kura Oncology; Macrogenics; Novartis; Pfizer; Schrodinger; SERVIER; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Takeda; Trillium Therapeutics
Speakers' Bureau - Abbvie; Agios; Bristol Myers Squibb Foundation; Incyte; Jazz Pharmaceuticals; Novartis; SERVIER; Syndax
Research Funding - Abbvie (Inst); Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Aptose Biosciences (Inst); Ascentage Pharma (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Glycomimetics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Macrogenics (Inst); Novartis (Inst); Oryzon Genomics (Inst); PTC Therapeutics (Inst); SERVIER (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Celgene; Glycomimetics
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo
 
Eunice Wang
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Immunogen; Johnson & Johnson/Janssen; Kite/Gilead; Kura Oncology; Novartis; Qiagen; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER; Stemline Therapeutics; Sumitomo Pharma Oncology; Syndax; Takeda
Speakers' Bureau - Astellas Pharma; Daiichi Sankyo/UCB Japan; DAVA Pharmaceuticals; Pfizer
Other Relationship - Abbvie/Genentech; Gilead Sciences; Gilead Sciences; UpToDate
 
Roland Walter
Consulting or Advisory Role - Abbvie; Adicet Bio; BerGenBio; Bristol-Myers Squibb/Celgene/Juno; GlaxoSmithKline; Kura Oncology; Orum Therapeutics; WUGEN, Inc.
Research Funding - Amgen (Inst); Aptevo Therapeutics (Inst); Immunogen (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Kite/Gilead; Kura Oncology (Inst); Macrogenics (Inst); Pfizer; Vor Biopharma (Inst)
 
Eric Deconinck
Consulting or Advisory Role - Stemline Therapeutics
Research Funding - Abbvie (Inst); ImmunoGen (Inst); Janssen (Inst); Novartis/Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Grifols; ImmunoGen; Janssen-Cilag; Novartis/Pfizer; Stemline Therapeutics
 
Ahmed Aribi
Consulting or Advisory Role - Seagen; Seagen
 
Ollivier Legrand
No Relationships to Disclose
 
Delphine Lebon
No Relationships to Disclose
 
Giovanni Martinelli
Employment - University of Bologna, Bologna, Italy
 
Daniel DeAngelo
Consulting or Advisory Role - Amgen; Blueprint Medicines; Gilead Sciences; Incyte; Jazz Pharmaceuticals; Novartis; Pfizer; servier; takeda
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); glycomimetics (Inst); Novartis (Inst)
 
Yining Du
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jalaja Potluri
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Naval Daver
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)